Plancorp LLC Has $559,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Plancorp LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.5% in the fourth quarter, Holdings Channel reports. The institutional investor owned 6,054 shares of the biopharmaceutical company’s stock after buying an additional 150 shares during the period. Plancorp LLC’s holdings in Gilead Sciences were worth $559,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GILD. State Street Corp increased its stake in Gilead Sciences by 1.4% in the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock valued at $5,044,795,000 after acquiring an additional 841,776 shares during the last quarter. Wellington Management Group LLP increased its stake in Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after acquiring an additional 11,665,593 shares during the last quarter. FMR LLC increased its stake in Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after acquiring an additional 14,680,161 shares during the last quarter. Geode Capital Management LLC increased its stake in Gilead Sciences by 2.1% in the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock valued at $2,302,119,000 after acquiring an additional 574,421 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Gilead Sciences by 3.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,002,779 shares of the biopharmaceutical company’s stock valued at $739,217,000 after acquiring an additional 249,804 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $107.08 on Friday. The firm’s 50-day moving average price is $103.68 and its 200-day moving average price is $93.85. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The firm has a market capitalization of $133.35 billion, a P/E ratio of 289.41, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date is Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the sale, the chief financial officer now owns 169,061 shares in the company, valued at $19,977,938.37. This represents a 9.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold 302,785 shares of company stock worth $30,503,250 in the last quarter. Insiders own 0.29% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Oppenheimer lifted their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research note on Tuesday, March 4th. Piper Sandler boosted their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. Royal Bank of Canada boosted their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. DZ Bank raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research note on Thursday, February 13th. Finally, Morgan Stanley boosted their target price on shares of Gilead Sciences from $123.00 to $130.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 11th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $104.52.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.